Markets News

Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.

Standard Chartered CFO Exits Ahead of Earnings, Shares Drop Over 4%
Markets Daniel Marsh

Standard Chartered CFO Exits Ahead of Earnings, Shares Drop Over 4%

Standard Chartered shares fell sharply after CFO Diego De Giorgi departed for Apollo, with the bank naming an interim finance chief weeks before its full-year results.

APO
Eddie Bauer Retail Arm Files Chapter 11, Launches Store Liquidation
Markets Daniel Marsh

Eddie Bauer Retail Arm Files Chapter 11, Launches Store Liquidation

The operator of Eddie Bauer's physical stores has initiated Chapter 11 bankruptcy proceedings, commencing going-out-of-business sales at approximately 180 locations across North America while seeking a buyer by mid-March.

Markets Await Retail Sales Data and Treasury Auction Amid Flat Futures
Markets Daniel Marsh

Markets Await Retail Sales Data and Treasury Auction Amid Flat Futures

U.S. stock futures held steady early Tuesday as investors braced for December retail sales figures and a $58 billion 3-year Treasury note auction. The Dow closed at a record high for a second consecutive session on Monday.

ON
Futures Inch Higher Ahead of Key Retail Sales, Earnings Reports
Markets Daniel Marsh

Futures Inch Higher Ahead of Key Retail Sales, Earnings Reports

U.S. stock futures edged up Tuesday as investors awaited crucial retail sales data and earnings from Coca-Cola and Ford. The S&P 500 futures rose 0.08%, while Dow futures added 45 points.

KO F META NVDA TSLA AAPL XLK
FTSE 100 Slips as BP Pauses Buybacks, StanChart Dives; AstraZeneca Gains
Markets Daniel Marsh

FTSE 100 Slips as BP Pauses Buybacks, StanChart Dives; AstraZeneca Gains

The FTSE 100 fell 0.4% early Tuesday, pressured by sharp declines in BP and Standard Chartered, while AstraZeneca climbed on a solid outlook. Sterling weakened amid political and rate uncertainty.

BP AZN BCS BCS GLD USO XLE XLF XLV
Dow Futures Edge Higher Ahead of Key Economic Data Releases
Markets Daniel Marsh

Dow Futures Edge Higher Ahead of Key Economic Data Releases

Dow Jones futures advanced slightly Tuesday as investors await retail sales figures, with payroll and inflation reports due later this week. Tech stocks led Monday's market recovery.

DIA SPY QQQ XLK MRNA MRK
Indian Equities Extend Gains on Foreign Inflows and Trade Optimism
Markets Daniel Marsh

Indian Equities Extend Gains on Foreign Inflows and Trade Optimism

Indian benchmarks rose for a third consecutive session, supported by foreign portfolio investments and optimism around a U.S. trade framework. Auto and metal stocks led the advance.

ASX 200 Ends Flat Amid AI Jitters; CSL Tumbles on CEO Exit
Markets Daniel Marsh

ASX 200 Ends Flat Amid AI Jitters; CSL Tumbles on CEO Exit

The S&P/ASX 200 closed virtually unchanged, dipping 2.7 points to 8,867.40. Insurance brokers slumped on AI competition fears, while CSL fell 5% after its CEO announced retirement.

CSL ASX XLF XLV
Transocean's $5.8B Valaris Acquisition Sparks Pre-Market Rally
Markets Daniel Marsh

Transocean's $5.8B Valaris Acquisition Sparks Pre-Market Rally

Transocean shares climbed 6% premarket after announcing an all-stock merger with Valaris, creating a combined fleet of 73 rigs with a $10 billion backlog.

RIG VAL
Valaris Shares Retreat in Premarket Following Transocean Acquisition-Driven Surge
Markets Daniel Marsh

Valaris Shares Retreat in Premarket Following Transocean Acquisition-Driven Surge

Valaris stock declined 2% in premarket trading after a 34% rally on news of an all-stock takeover by Transocean, valued at $82.12 per share.

RIG VAL
Abpro Holdings Soars 94% Premarket on Goldman Sachs Stake Disclosure
Markets Daniel Marsh

Abpro Holdings Soars 94% Premarket on Goldman Sachs Stake Disclosure

Abpro Holdings shares surged nearly 94% in premarket trading after a regulatory filing revealed Goldman Sachs holds a 6.8% passive stake in the biotech firm.

ABP
Quince Therapeutics Engages LifeSci for Strategic Review Amid Phase 3 Setback
Markets Daniel Marsh

Quince Therapeutics Engages LifeSci for Strategic Review Amid Phase 3 Setback

Quince Therapeutics shares fell 6.6% in premarket trading after hiring LifeSci Capital to explore strategic alternatives and debt restructuring, following a failed Phase 3 trial and board resignations.

QNCX